hepatitis b an update on treatment

33

Upload: astro

Post on 19-Jan-2016

47 views

Category:

Documents


0 download

DESCRIPTION

www.drsarma.in. HEPATITIS B AN UPDATE ON TREATMENT. Dr. R V S N Sarma MD MSc (Canada) FIMSA Consultant Physician and Cardio Metabolic Specialist. Who should be treated ?. When to treat in HBV course ? What is the treatment ?. Goal of Antiviral Therapy. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: HEPATITIS B   AN  UPDATE ON TREATMENT
Page 2: HEPATITIS B   AN  UPDATE ON TREATMENT
Page 3: HEPATITIS B   AN  UPDATE ON TREATMENT

1. Sustained suppression of HBV replication

Decrease in serum HBV DNA to <105 copies/ml

Seroconversion HBeAg to anti-HBe; HBsAg to anti-HBs

2. Remission of liver disease; Normalization of serum

ALT levels

Decreased necro-inflammation in liver

3. Improvement in clinical outcome; Decreased risks of

developing cirrhosis, liver failure and HCC;

4. Increased survival

Page 4: HEPATITIS B   AN  UPDATE ON TREATMENT

Patients who have

• Acute liver failure due to HBV

• ALT of >2 x UNL and or HBV DNA > 20,000 IU/ml

• Cirrhosis and clinical complications

• Cirrhosis or advanced fibrosis & HBV DNA in serum

• Reactivation of Chronic HBV after chemotherapy or immuno-suppression

• Infants born to women who are HBsAg-positive

• The immune-active phase who do not have advanced fibrosis or cirrhosis

Page 5: HEPATITIS B   AN  UPDATE ON TREATMENT

Patients with

• Chronic hepatitis B in the immune-tolerant phase (with high levels of serum HBV DNA but normal serum ALT levels or little activity on liver biopsy)

• Patients in the inactive carrier or low replicative phase (with low levels of or no detectable HBV DNA in serum and normal serum ALT levels)

• Patients who have latent HBV infection (HBV DNA without HBsAg)

Page 6: HEPATITIS B   AN  UPDATE ON TREATMENT

• High baseline ALT level

• Low Baseline HBV DNA level

• Mild-to-moderate histological activity

• Mild to Moderate stage Liver Dysfunction

• Genotype of the HBV – (A>B>C>D)

• Baseline HBeAg positivity (wild virus)

• Genetic barrier to resistance - Lamivudine, Telbivudine and to a lesser degree, Adefovir

Page 7: HEPATITIS B   AN  UPDATE ON TREATMENT

• Persistently elevated HBV DNA

• Persistently elevated ALT (SGPT)

• HBV genotype C infection

• Male Gender, Older age

• Family history of HCC

• Co-infection with HCV or HIV or HDV

Page 8: HEPATITIS B   AN  UPDATE ON TREATMENT
Page 9: HEPATITIS B   AN  UPDATE ON TREATMENT
Page 10: HEPATITIS B   AN  UPDATE ON TREATMENT
Page 11: HEPATITIS B   AN  UPDATE ON TREATMENT
Page 12: HEPATITIS B   AN  UPDATE ON TREATMENT
Page 13: HEPATITIS B   AN  UPDATE ON TREATMENT
Page 14: HEPATITIS B   AN  UPDATE ON TREATMENT

Obtain Baseline testsObtain Baseline tests

HBV DNA, ALTHBV Serology panel

Page 15: HEPATITIS B   AN  UPDATE ON TREATMENT

Obtain Baseline testsObtain Baseline tests

HBV DNA, ALTHBV Serology panel

Page 16: HEPATITIS B   AN  UPDATE ON TREATMENT

Endocrine

Hypothyroidism

Hyperthyroidism

Dermatologic

Rash, Dry skin, Pruritus

Thinning of Hair

Gastrointestinal

Anorexia, Nausea, Weight loss

Systemic

Fever (low grade), Fatigue

Myalgia and or Arthralgia

Mood Disturbances

Depression

Irritability, Insomnia

Hematologic

Neutropenia, Anemia

Thrombocytopenia

Page 17: HEPATITIS B   AN  UPDATE ON TREATMENT
Page 18: HEPATITIS B   AN  UPDATE ON TREATMENT
Page 19: HEPATITIS B   AN  UPDATE ON TREATMENT
Page 20: HEPATITIS B   AN  UPDATE ON TREATMENT
Page 21: HEPATITIS B   AN  UPDATE ON TREATMENT
Page 22: HEPATITIS B   AN  UPDATE ON TREATMENT
Page 23: HEPATITIS B   AN  UPDATE ON TREATMENT
Page 24: HEPATITIS B   AN  UPDATE ON TREATMENT
Page 25: HEPATITIS B   AN  UPDATE ON TREATMENT
Page 26: HEPATITIS B   AN  UPDATE ON TREATMENT
Page 27: HEPATITIS B   AN  UPDATE ON TREATMENT
Page 28: HEPATITIS B   AN  UPDATE ON TREATMENT
Page 29: HEPATITIS B   AN  UPDATE ON TREATMENT
Page 30: HEPATITIS B   AN  UPDATE ON TREATMENT
Page 31: HEPATITIS B   AN  UPDATE ON TREATMENT

105 copies/ml(20,000 IU/ml)

Page 32: HEPATITIS B   AN  UPDATE ON TREATMENT

• Emtricitabine

• Clevudine (l-FMAU)

• Therapeutic vaccines

Page 33: HEPATITIS B   AN  UPDATE ON TREATMENT